Sertoli-Leydig cell tumor associated with a germline DICER1 pathogenic variant diagnosed during pregnancy: Considerations for treatment, surveillance, and prevention.
Gynecol Oncol Rep
; 48: 101215, 2023 Aug.
Article
en En
| MEDLINE
| ID: mdl-37334322
ABSTRACT
â¢This is the first report of a germline DICER1-associated Sertoli-Leydig cell tumor (SLCT) diagnosed in pregnancy.â¢SLCT is linked to DICER1 pathogenic variants, but little is known about management of DICER1-associated SLCT.â¢There is an extended risk for metachronous SLCT in patients with germline DICER1 pathogenic variants who retain an ovary.â¢Prophylactic contralateral salpingo-oophorectomy may be offered with shared decision making to patients with inherited SLCT.â¢Genetic testing for DICER1 should be offered to all patients with moderately or poorly differentiated SLCT.
Texto completo:
1
Bases de datos:
MEDLINE
Tipo de estudio:
Diagnostic_studies
/
Prognostic_studies
/
Risk_factors_studies
/
Screening_studies
Idioma:
En
Revista:
Gynecol Oncol Rep
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos